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AbstrAct
Introduction Raynaud’s phenomenon (RP) describes 
excessive peripheral vasospasm to cold exposure and/
or emotional stress. RP episodes are associated with 
digital colour changes, pain and reduced quality of life. 
Pharmacological interventions are of low to moderate 
efficacy and often result in adverse effects such as 
facial flushing and headaches. Recommended lifestyle 
and behavioural interventions have not been evaluated. 
The objectives of the proposed systematic review are to 
assess the comparative safety and efficacy of behaviour 
change interventions for RP and identify what we can 
learn to inform future interventions.
Methods and analysis Studies eligible for inclusion 
include randomised controlled trials testing behaviour 
change interventions with a control comparator. A 
comprehensive search strategy will include peer review 
and grey literature up until 30 April 2017. Search 
databases will include Medline, Embase, PsychINFO and 
Cochrane. Initial sifting, eligibility, data extraction, risk of 
bias and quality assessment will be subject to review by 
two independent reviewers with a third reviewer resolving 
discrepancies. Risk of bias assessment will be performed 
using Cochrane risk of a bias assessment tool with quality 
of evidence assessed using Grading of Recommendations 
Assessment, Development and Evaluation(GRADE). A 
meta-analysis will be performed if there are sufficient 
data. Two subgroup analyses are planned: primary versus 
secondary RP outcomes; comparison of theoretically 
informed interventions with pragmatic interventions.
Ethics and dissemination This review does not require 
ethical approval as it will summarise published studies 
with non-identifiable data. This protocol complies with 
the Preferred Reporting Items for Systematic Review and 
Meta-Analysis Protocols (PRISMA-P) guidelines. Findings 
will be disseminated in peer-reviewed articles and 
reported according to PRISMA. This review will make a 
significant contribution to the management of RP where 
no review of behaviour-change interventions currently 
exist. The synopsis and protocol for the proposed 
systematic review is registered in the International 
Prospective Register of Systematic Reviews (registration 
number CRD42017049643).
IntroductIon
Peripheral vasoconstriction of thermo-
regulatory precapillary arterioles and 
arteriovenous anastomoses is a normal phys-
iological response to cold exposure designed 
to preserve normal core temperature.1Ray-
naud’s phenomenon (RP) describes excessive 
peripheral vasospasm to cold exposure and/
or emotional stress. Attacks of RP are associ-
ated with characteristic digital colour changes 
(reflecting blood oxygenation and tissue 
perfusion). Tissue ischaemia (and subsequent 
reperfusion) during attacks of RP results in 
pain and paraesthesia causing distress, loss 
of hand function and reduced quality of life. 
RP is common, affecting approximately 10% 
of people.2 The majority of patients with RP 
have a functional vasospastic disorder which, 
while intrusive, is otherwise benign in nature 
(termed primary RP). Digital perfusion 
is generally normal in between attacks. In 
other circumstances, symptoms of RP occur 
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Protocol
strengths and limitations of this study
 ► This study will offer the first review of behaviour-
change interventions for the treatment of Raynaud’ s 
phenomenon (RP), making a significant contribution 
to our current understanding of treatment options 
and interventions for this common medical 
complaint.
 ► Risk of bias assessment will be performed 
using the  Cochrane risk of bias assessment 
tool with quality of evidence assessed using 
GRADE. We will also assess for quality of each 
psychotherapeutic intervention, further comparing 
theoretically  underpinned and pragmatic 
interventions.
 ► We will restrict our review to randomised controlled 
trials only, which may exclude studies of potential 
interest. However, we aim to evaluate efficacy of 
high-quality interventions and use the outcomes of 
this review to inform future high-quality interventions 
for RP, therefore we believe this exclusion is 
appropriate. We intend to discuss noteworthy non-
randomised trials or observational studies, however 
this will not be part of our specified search.
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as a result of disturbed digital tissue perfusion related to 
separate underlying pathology (termed secondary RP). 
Important causes of secondary RP are the autoimmune 
rheumatic diseases such as systemic sclerosis (SSc). In 
SSc, endothelial damage leads to an obliterative microan-
giopathy, characterised by structural changes to the vessel 
wall and near permanent tissue ischaemia. SSc, despite 
being rare with an estimated prevalence of 250/million,3 
is often used as the focus of RP research. Cold expo-
sure is the most frequent precipitating factor, although 
emotional stress may account for up to a third of RP 
attacks.4
Behavioural approaches to RP management include 
lifestyle and habit reversal interventions such as 
avoiding cold exposure, conserving heat loss, smoking 
cessation, increasing exercise and reducing stress 
levels.5 It is recognised that adherence with inter-
ventions of this nature can be poor with estimates of 
30%–50% of patients demonstrating poor compliance, 
regardless of condition, expected outcome or setting.6 
Pharmacological interventions to induce vasodilation 
and prevent excessive vasoconstriction of the digital 
microvasculature also have a role in RP management 
but the efficacy of such treatments is modest in terms 
of frequency and severity of RP attacks.7 Furthermore, 
pharmacological intervention to promote vasodilation 
often results in adverse effects such as facial flushing, 
headaches, fluid retention, dizziness and palpitations.8 
Despite the perceived importance of non-pharmacolog-
ical interventions, comparative efficacy, adoption and 
compliance with lifestyle interventions has not been 
fully evaluated.5 A number of behavioural interventions 
have been tested for RP but the comparative efficacy of 
a range of interventions within different disease popu-
lations (primary and secondary RP) has not previously 
been the focus of a systematic review. The specific objec-
tives of the proposed systematic review are to assess the 
comparative safety and efficacy of a range of behavioural 
interventions for the management and treatment of 
symptoms associated with primary and secondary RP. 
The secondary objective is to identify what we can learn 
from the studies reviewed to inform future behaviour 
change interventions for RP.
MEthods And AnAlysIs
Reporting of protocol and review registration
This protocol follows PRIMSA-P guidelines9 for the 
reporting of a systematic review protocol (online supple-
mentary table 1). The synopsis and protocol for this 
systematic review is registered in the International 
Prospective Register of Systematic Reviews (http://www. 
crd. york. ac. uk/ PROSPERO),%20registration number 
CRD42017049643.10 Reference was also made to the 
generic Cochrane protocol for pharmacological interven-
tions for the treatment of RP.11
study selection
Randomised controlled trials (RCTs) testing one or more 
active treatment interventions with a control compar-
ator arm will be included. Both individual and cluster 
randomisation will be included providing cluster sites 
meet other inclusion criteria. Non-RCTs and other inter-
vention study designs will not be included. Blinding in 
non-pharmacological interventions is not always possible 
or relevant. Non-blinded studies will be included.
Participants
Adults (18 years or older) with a diagnosis of RP (primary 
or secondary). Mixed samples studies will be included. 
The search will be limited to studies with humans.
Interventions
We define behaviour change interventions as interventions 
which target symptomatic relief of RP through directed or 
advised change in patient-determined behaviour. We are 
particularly interested in studies consistent with National 
Institute for Health and Care Excellence guidelines for 
RP,5 however we purposefully include all interventions 
which are designed to change behaviour to improve 
symptoms. Behaviour change interventions are described 
variably and may use the following adjectives, all of which 
will be used in the search strategy: behavio(u)ral therapy, 
cognitive therapy, education, psychoeducation, biofeed-
back, clinical psychology, psychological, psychotherapy, 
self-management, cognitive behavio(u)r therapy and 
behavioural medicine.
outcome measures
There is no consensus over the domains of measurement 
or measurement technology.12
Assessment of RP is largely reliant on patient-re-
ported outcomes, typically captured using instruments 
that monitor RP symptoms over 1–2 weeks (such as the 
Raynaud's Condition Score (RCS) diary).13 The primary 
outcome measures chosen for our analyses mirror those 
adopted in a recent generic systematic review protocol 
for RP11 and include: the severity/impact of RP episodes 
assessed using Visual Analogue Scales (VAS); Likert 
Scales or the RCS either at a single time point (using a 
standardised recall period) or as an average daily score 
(obtained from the RCS diary or equivalent from RP 
symptom diary); frequency of RP attacks (adopted from 
the RCS diary or equivalent symptom diary approach) 
reported as average daily or weekly frequency of RP 
attacks; duration of RP attacks (adopted from the RCS 
diary or equivalent symptom diary approach) reported as 
the average daily duration of RP attacks over 1–2 weeks; 
pain assessed using a VAS or Likert Scale (reporting inten-
sity of pain during RP attacks) and patient assessment 
of disability due to RP/interference on daily activities, 
for example, the Scleroderma Health Assessment Ques-
tionnaire (HAQ) RP VAS or equivalent. Adverse events 
(hospitalisation/death) and withdrawals from study will 
also be included within our primary outcomes.
Secondary outcomes will include physician global assess-
ment of severity/impact of RP; patient global assessment 
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of function/disability secondary to RP (eg, the HAQ 
Score); change in digital ulceration (positive/negative); 
treatment preference and general improvement (self-re-
ported overall improvement). Outcome data on anxiety 
and depression will also be collated where available. Most 
RP clinical trials involve assessments over one or more 
weeks. Sensitivity analyses shall be undertaken if the anal-
yses include trials with marked differences in duration of 
treatment/assessment.
search strategy
A comprehensive search strategy has been created, which 
includes searching of grey literature. Four sources of 
peer-review databases will be used: Medline, Embase, 
PsychINFO and Cochrane. The search will have no 
language or publication date restrictions, seeking to 
translate where necessary. Studies must be fully published 
at the time of search; early view online publications will be 
included. A draft search strategy is included in the online 
supplementary tables 2 and 3. Endnote and Covidence 
software ( covidence. org) will be used for data manage-
ment.
selection of studies
All studies generated by the search will be screened by two 
review authors for eligibility. Full texts will be retrieved 
for those which meet eligibility, which will then be rated 
independently by two review authors using a prespeci-
fied data extraction form (online supplementary tables 
4 and 5). Bibliographies of included studies will also be 
searched for inclusion of relevant studies, which will then 
be subject to independent review of eligibility. Discrepan-
cies will be reviewed, with resolution through discussion 
and consultation of a third author reviewer. Level of 
agreement will be calculated.
data collection process
All eligible studies will be subject to independent data 
extraction by two review authors. A data extraction form 
has been iteratively developed and piloted to extract the 
following information from included studies: full citation 
including author and year of publication; retrieval infor-
mation(date/database); patient population; diagnostic 
criteria used for RP diagnosis; study design; interven-
tion(s); study setting/county (including language); 
format of intervention (eg, group/individual/internet); 
sample size and description; age/gender/ethnicity/
intervention(s); duration of study; number of treat-
ment sessions; primary endpoints; secondary outpoints; 
frequency, duration and severity of RP attacks; outcome/
results; comments, adverse events.
We will also collect information pertaining to the 
quality of psychotherapeutic interventions: (1) reference 
to a theoretical model (2) level of therapist training (3) 
whether the integrity of the intervention was checked. 
These criteria are drawn from an authoritative review of 
empirically supported psychotherapies.14 We will attempt 
to retrieve missing data with study authors.
The data extraction form will feature a brief eligibility 
check box with core inclusion criteria: adults with RP; 
behaviour change intervention with at least one compar-
ator; RCT; RCS or equivalent. All criteria need to be 
present in order to demonstrate eligibility.
risk of bias
Two review authors will independently assess risk of bias 
on an outcome and study level using the Cochrane risk 
of bias assessment tool. Unresolved discrepancies will be 
reviewed by the third review author. We will assess risk 
of bias according to the following dimensions: random 
sequence generation (adequate description and method 
of participant allocation in accordance with standard 
randomisation); allocation concealment (adequate 
concealment of group assignment to prevent selection 
bias); blinding of participants and personnel (adequacy 
of measures taken to prevent performance bias and 
conceal group assignment); blinding outcome asses-
sors (adequacy of measures taken to prevent detection 
bias and conceal group assignment to outcome asses-
sors); incomplete data (adequacy of the management of 
missing data and potential implications for bias); selective 
outcome reporting (reporting bias relating to the consis-
tency between prespecified and reported outcomes); 
other sources of bias (other concerns not covered else-
where but may lead to a risk of bias). All eligible studies 
will be rated as high, low or unclear (risk of bias), on each 
of these dimensions, culminating in an overall risk of 
bias (high/low/unclear) in accordance with the Cochrane 
Handbook for Systematic Reviews of Interventions.15 Funnel 
plots will be used to assess bias and will be stratified based 
on bias assessment, if considered useful and appropriate 
(>10 studies).
Quality of evidence
We will assess the quality of the evidence, and so our 
confidence in any estimates of effect using Grading of 
Recommendations Assessment, Development and Eval-
uation(GRADE): (in)consistency of effect, imprecision, 
indirectness and publication bias.16 If possible we will 
construct a GRADE summary of findings table, using the 
seven primary outcomes. Where possible, we will express 
dichotomous outcomes, e.g. no less than mild pain 
defined as <30 on a 100-point scale,17 or 50% reduction in 
the number of episodes, or minimally clinically important 
differences (MCID).18
AnAlysIs
We will perform a meta-analysis if there are sufficient 
data, and it is clinically sensible.
Effect sizes will be calculated at post-test between ther-
apies for each comparison with control (using hedges g) 
by subtracting average score of active arm from average 
of control arm and dividing by pooled SD. We will also 
calculate mean/median differences from baseline to 
post-treatment for each invention and mean differences 
of change in measures associated with primary outcomes 
(where appropriate).
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The review outcomes are likely to be reported in both 
dichotomous and continuous data. For dichotomous 
data we will report the results as summary of risk ratios 
and CI levels of 95%, pooling those data with identical 
outcomes and interventions. For continuous data, stan-
dardised mean difference and 95% CI will be used due 
to likelihood of discrepant scales used in the study. 
The Cochrane handbook will be used for translation of 
outcomes of scales.
Heterogeneity will be assessed on the basis of study 
design, participants, interventions and outcomes and will 
be assessed using forest plots (using 10% level). Higgins 
I2 statistic, X2 and visual inspection of forest plots will be 
used to assess homogeneity with thresholds of 50%–75% 
for moderate heterogeneity and 75% for significant 
heterogeneity. We anticipate the use of random-effects 
meta-analysis due to the likely heterogeneity of partic-
ipant and outcomes data, however fixed models will be 
used where appropriate.
In the absence of a meta-analysis, a narrative (descrip-
tive) analysis of primary and secondary outcomes will 
be provided and will include: (1) aggregated data on 
mean daily frequency/severity/duration of episodes, 
patient global assessment of disability and changes in 
RCS (2) analysis of reported design or intervention 
flaws in behaviour change interventions (3) analysis 
of study reported outcomes and/or limitations, for the 
purposes of informing future behaviour change interven-
tions for Raynaud's Phenomenon.
Due to the lack of consesus over reliable measurement 
endpoints in RP treatment trials, we will specify MCIDs 
measures to allow clinically meaningful interpretation 
of change on standardised measures. More specifically: 
15-point difference on RCS, 20% difference on VAS and 
Likert Scales (based previous estimates in RP12), use 
of Reliable Change Index19 for other standardised 
measures.
Planned subgroup analysis
Two subgroup analyses are planned based on specific 
clinical hypotheses. First, we will analyse outcomes by diag-
nosis; studies will be divided (where possible) into primary 
versus secondary RP. Studies which combine both primary 
and secondary RP will only separate into two subgroups if 
data are available to do so. Evidence suggests that primary 
and secondary RP may have different underlying patho-
geneses, with studies reporting clear differences in onset, 
course and prognosis between the groups.20 Second, we 
will analyse outcomes based on the presence or absence 
of identified psychological model of behaviour change, 
comparing theoretically informed interventions with 
pragmatic interventions. Interventions that are empiri-
cally supported and evidence-based are more likely to be 
efficacious than their counterparts, therefore subdivision 
will allow us to identify whether there is a discrepancy and 
will allow a more meaningful interpretation of findings. 
Analysis of subgroups will include the aforementioned 
test of homogeneity to assess potential group effects, 
findings will be interpreted accordingly and further anal-
ysis performed where appropriate.
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